Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)
NCT ID: NCT06829225
Last Updated: 2025-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2024-06-13
2024-11-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)
NCT06821334
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects
NCT05308940
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants
NCT06086886
A Phase I Study of RC1416 Injection
NCT06067490
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants
NCT06476821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tulisokibart Dose 1 Treatment Subcutaneous (SC) Injection
Participants will receive a single SC injection dose of tulisokibart at dose 1 on Day 1.
Tulisokibart
SC Injection or IV Infusion
Placebo SC Injection
Participants will receive a single SC injection dose of placebo at on Day 1.
Placebo
Tulisokibart-matched Placebo SC Injection or IV Infusion
Tulisokibart Dose 1 Intravenous (IV) Infusion
Participants will receive a single IV infusion dose of tulisokibart at dose 1 on Day 1.
Tulisokibart
SC Injection or IV Infusion
Tulisokibart Dose 2 IV Infusion
Participants will receive a single IV infusion dose of tulisokibart at dose 2 on Day 1.
Tulisokibart
SC Injection or IV Infusion
Tulisokibart Dose 3 IV Infusion
Participants will receive a single IV infusion dose of tulisokibart at dose 3 on Day 1.
Tulisokibart
SC Injection or IV Infusion
Placebo IV Infusion
Participants will receive a single IV infusion dose of placebo on Day 1.
Placebo
Tulisokibart-matched Placebo SC Injection or IV Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tulisokibart
SC Injection or IV Infusion
Placebo
Tulisokibart-matched Placebo SC Injection or IV Infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a body mass index (BMI) ≥18 and ≤28 kg/m\^2 and weight ≥40.0 kg
* Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to the dosing of study drug
Exclusion Criteria
* Has positive serum test for human immunodeficiency virus (HIV), hepatitis C or hepatitis B virus infection
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Third Hospital (Site 0001)
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-7240-002
Identifier Type: OTHER
Identifier Source: secondary_id
7240-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.